{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:41Z","timestamp":1787027021127,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Both camrelizumab plus paclitaxel and carboplatin (CTC) and sintilimab plus gemcitabine and cisplatin or carboplatin (SGP) have been approved by the National Medical Products Administration of China (NMPA) for the first-line treatment of local advanced or metastatic sqNSCLC. However, the comparison of the two treatments as first-line treatments in efficacy or pharmacoeconomics has barely been studied. To deeply understand the costs and outcomes of the two treatments, this work directly compared the cost-effectiveness for the first-line treatment of local advanced or metastatic squamous NSCLC in the Chinese mainland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A network meta-analysis was first performed based on the three clinical trials, namely, CameL-Sq, ORIENT-12, and C-TONG1002, to compare the clinical benefits of the two treatments. The Weibull approximation was applied to further calculate the life expectancy of the two treatments. The partitioned survival model (PSM) was next established, and one-way sensitivity analysis and probabilistic sensitivity analysis were also performed to evaluate the stability of the underlying parameter values and assumptions within the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CTC treatment gained 0.68 QALYs and cost $14,764. SGP treatment gained 0.54 QALYs and cost $14,584. The CTC arm gained 0.14 additional QALYs and cost $179 more than the SGP arm, and the ICERs was $1,269\/QALY, which was lower than one-fold GDP\n                      <jats:italic>per capita<\/jats:italic>\n                      in the Chinese mainland ($12,734 GDP\n                      <jats:italic>per capita<\/jats:italic>\n                      in 2022). In probabilistic sensitivity analysis, when the WTP ranged from $12,734\u201338,202 (1\u20133 folds, 2022 GDP\n                      <jats:italic>per capita<\/jats:italic>\n                      in China), the CTC group had higher probabilities than the SGP group for being cost effective, which ranged from 85.65% to 88.38%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>From the perspective of the payers, camrelizumab plus chemotherapy was cost-effective compared with sintilimab plus chemotherapy for the first-line treatment of local advanced or metastatic squamous NSCLC in the Chinese mainland.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1356725","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:56:37Z","timestamp":1720745797000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaoting","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuirong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"12","author":"Bertram","year":"2016","journal-title":"Bull. World Health Organ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta3100","article-title":"Methods for the analysis of quality-of-life and survival data in health technology assessment","volume":"10","author":"Billingham","year":"1999","journal-title":"Health Technol. Assess. Winch. Engl."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.956792","article-title":"Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC","volume":"10","author":"Chen","year":"2022","journal-title":"Front. Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017","volume":"12","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.lungcan.2018.11.029","article-title":"Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China","volume":"127","author":"Gu","year":"2019","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"1","author":"Hoyle","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1080\/21645515.2021.1996151","article-title":"Incidence and disease burden of community-acquired pneumonia in southeastern China: data from integrated medical resources","volume":"12","author":"Jiang","year":"2021","journal-title":"Hum. Vaccin Immunother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2217\/imt-2023-0008","article-title":"Cost-effectiveness of camrelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer","volume":"15","author":"Liang","year":"","journal-title":"Immunotherapy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1009920","DOI":"10.3389\/fpubh.2023.1009920","article-title":"Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer","volume":"11","author":"Liang","year":"","journal-title":"Front. Public Health"},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13561-022-00410-x","article-title":"Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non\u2013small cell lung cancer in China","volume":"12","author":"Liu","year":"2022","journal-title":"Health Econ. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study","volume":"5","author":"Nafees","year":"2017","journal-title":"Asia Pac J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"4","author":"Ren","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/13696998.2022.2071066","article-title":"Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China","volume":"1","author":"Rui","year":"2022","journal-title":"J. Med. Econ."},{"key":"B17","doi-asserted-by":"publisher","first-page":"912921","DOI":"10.3389\/fpubh.2022.912921","article-title":"Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China","volume":"10","author":"Shao","year":"2022","journal-title":"Front. Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"928","DOI":"10.21037\/tcr-22-2030","article-title":"Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer","volume":"4","author":"Shi","year":"2023","journal-title":"Transl. Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","article-title":"Clinicopathologic features of advanced squamous NSCLC","volume":"9","author":"Socinski","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/j.ejca.2006.08.010","article-title":"Methodological issues in the economic analysis of cancer treatments","volume":"42","author":"Tappenden","year":"2006","journal-title":"Eur. J. cancer (Oxford, Engl. 1990)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","article-title":"Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia","volume":"5","author":"Tolley","year":"2012","journal-title":"Eur. J. Health Econ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1002\/cncr.32368","article-title":"First\u2010line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non\u2013small cell lung cancer: a United States\u2013based cost\u2010effectiveness analysis","volume":"20","author":"Wan","year":"2019","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2019.01.007","article-title":"A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)","volume":"109","author":"Wang","year":"2019","journal-title":"Eur. J. cancer (Oxford, Engl. 1990)"},{"key":"B24","unstructured":"NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review\n            WoodsB.\n            SiderisE.\n            PalmerS.\n            LatimerN.\n            SoaresM.\n          2017"},{"key":"B25","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","year":"2003"},{"key":"B26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/1471-2407-14-984","article-title":"Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy","volume":"1","author":"Wu","year":"2014","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidel ines for universal health coverage in China","volume":"24","author":"Yue","year":"2021","journal-title":"Value Health Reg. Issues"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1169752","DOI":"10.3389\/fimmu.2023.1169752","article-title":"Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1051484","DOI":"10.3389\/fpubh.2023.1051484","article-title":"Effectiveness and cost-effectiveness analysis of 11 treatment paths, s even first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: a sequent ial model","volume":"11","author":"Zhao","year":"2023","journal-title":"Front. public health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"1","author":"Zheng","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","article-title":"Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12)","volume":"9","author":"Zhou","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1002\/cam4.3845","article-title":"Estimated annual prevalence, medical service utilization and direct co sts of lung cancer in urban China","volume":"8","author":"Zhu","year":"2021","journal-title":"Cancer Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1356725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:56:41Z","timestamp":1720745801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1356725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":32,"alternative-id":["10.3389\/fphar.2024.1356725"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1356725","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"article-number":"1356725"}}